Your browser doesn't support javascript.
loading
Stratifying elicited antibody dynamics after two doses of SARS-CoV-2 vaccine in a community-based cohort in Fukushima, Japan
Naotoshi Nakamura; Yurie Kobashi; Kwang Su Kim; Yuta Tani; Yuzo Shimazu; Tianchen Zhao; Yoshitaka Nishikawa; Fumiya Omata; Moe Kawashima; Makoto Yoshida; Toshiki Abe; Yoshika Saito; Yuki Senoo; Saori Nonaka; Morihito Takita; Chika Yamamoto; Takeshi Kawamura; Akira Sugiyama; Aya Nakayama; Yudai Kaneko; Hyeongi Park; Yong Dam Jeong; Daiki Tatematsu; Marwa Akao; Yoshitaka Sato; Shoya Iwanami; Yasuhisa Fujita; Masatoshi Wakui; Kazuyuki Aihara; Tatsuhiko Kodama; Kenji Shibuya; Shingo Iwami; Masaharu Tsubokura.
Afiliação
  • Naotoshi Nakamura; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Yurie Kobashi; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. Department of General Internal Medicine, Hirata Ce
  • Kwang Su Kim; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. Department of Science Sy
  • Yuta Tani; Medical Governance Research Institute,Tokyo, Japan.
  • Yuzo Shimazu; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Tianchen Zhao; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Yoshitaka Nishikawa; Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan.
  • Fumiya Omata; Department of General Internal Medicine, Hirata Central Hospital, Fukushima, Japan.
  • Moe Kawashima; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Makoto Yoshida; Medical Governance Research Institute,Tokyo, Japan.
  • Toshiki Abe; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Yoshika Saito; Medical Governance Research Institute,Tokyo, Japan.
  • Yuki Senoo; Medical Governance Research Institute,Tokyo, Japan.
  • Saori Nonaka; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Morihito Takita; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Chika Yamamoto; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan.
  • Takeshi Kawamura; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan. Laboratory for Systems Biology and Medicine, Research Center for Advanced
  • Akira Sugiyama; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan.
  • Aya Nakayama; Proteomics Laboratory, Isotope Science Center, The University of Tokyo, Tokyo, Japan.
  • Yudai Kaneko; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. Medical & Biological La
  • Hyeongi Park; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Yong Dam Jeong; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. Department of Mathematic
  • Daiki Tatematsu; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Marwa Akao; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Yoshitaka Sato; Department of Virology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Shoya Iwanami; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Yasuhisa Fujita; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan.
  • Masatoshi Wakui; Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kazuyuki Aihara; International Research Center for Neurointelligence, The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Tokyo, Japan.
  • Tatsuhiko Kodama; Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
  • Kenji Shibuya; Soma Medical Center for vaccination for COVID-19, Fukushima, Japan. Tokyo Foundation for Policy Research, Tokyo, Japan.
  • Shingo Iwami; interdisciplinary Biology Laboratory(iBLab), Division of Natural Science, Graduate School of Science, Nagoya University, Nagoya, Japan. Institute of Mathematics
  • Masaharu Tsubokura; Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima, Japan. Department of General Internal Medicine, Hirata Ce
Preprint em Inglês | medRxiv | ID: ppmedrxiv-22276266
ABSTRACT
Recent studies have provided insights into the effect of vaccine boosters on recall immunity. Given the limited global supply of COVID-19 vaccines, identifying vulnerable populations with lower sustained vaccine-elicited antibody titers is important for targeting individuals for booster vaccinations. Here we investigated longitudinal data in a cohort of 2,526 people in Fukushima, Japan, from April 2021 to December 2021. Antibody titers following two doses of a COVID-19 vaccine were repeatedly monitored and information on lifestyle habits, comorbidities, adverse reactions, and medication use was collected. Using mathematical modeling and machine learning, we stratified the time-course patterns of antibody titers and identified vulnerable populations with low sustained antibody titers. Moreover, we showed that only 5.7% of the participants in our cohort were part of the "durable" population with high sustained antibody titers, which suggests that this durable population might be overlooked in small cohorts. We also found large variation in antibody waning within our cohort. There is a potential usefulness of our approach for identifying the neglected vulnerable population.
Licença
cc_by_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...